Breakthrough T1D Awards Grant to Support PRISE‑hATG Study of SAB‑142 in Stage 3 Type 1 Diabetes
Breakthrough T1D awarded a grant to support the PRISE-hATG study, an investigator-led trial evaluating SAB-142 in Type 1 Diabetes patients diagnosed 100 days to 2 years ago. This study complements SAB Bio’s ongoing Phase 2b SAFEGUARD trial, which focuses on newly diagnosed patients, by assessing the drug’s ability to preserve beta cell function in a later-stage population.
Key figures
- Drug Name
- SAB-142
- Phase Of Trial
- investigator-led study (complementary to Phase 2b)
- Study name
- PRISE-hATG
- Target population
- Stage 3 T1D patients 100 days to 2 years from diagnosis
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.